StocksMedium•16 October 2026•
1 min read
FDA Approves UCB's ZILBRYSQ Autoinjector for Generalized Myasthenia Gravis
Key Facts
1The FDA approved UCB's ZILBRYSQ autoinjector for generalized myasthenia gravis, providing a once-daily self-administration option.
The FDA approved UCB's ZILBRYSQ autoinjector for the treatment of generalized myasthenia gravis. Benzinga reported that the device provides a once-daily self-administration option, allowing patients to manage their treatment independently.
This regulatory milestone aims to provide a more convenient delivery method for those suffering from the rare autoimmune neuromuscular disease. The approval marks a significant step in the biotech and healthcare sector's efforts to enhance patient care through innovative home-use medical devices.